The comparoison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor

Yonsei Medical Journal

Volumn 43, Issue 6, 2002, Pages 691-700

  Kim, Dong Kyu ^a   Kim, Jong Hwa ^a   Kim, Young Tae ^a   Kim, Jae Wook ^a   Ioannides, Constantin G ^b  

^a Yonsei University College of Medicine   (South Korea)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytotoxic T lymphocytes; Folate binding protein; IL 15; IL 2; Tumor associated lymphocytes

Indexed keywords

CD8 ANTIGEN; CELL PROTEIN; EPITOPE; FOLATE BINDING PROTEIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECEPTOR SUBTYPE; T LYMPHOCYTE RECEPTOR; CARRIER PROTEIN; CELL SURFACE RECEPTOR; FOLATE-BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MACROPHAGE; MOLECULAR RECOGNITION; MONOCYTE; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SOLID TUMOR; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; BREAST TUMOR; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; IMMUNOLOGY; MIDDLE AGED; OVARY TUMOR; PHYSIOLOGY;

BREAST NEOPLASMS; CARRIER PROTEINS; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036882318     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2002.43.6.691     Document Type: Article

References (36)

1. Ressing ME, Offringa R, Toes REM, Ossendorp F, Jong JH, Brandt RMP, et al. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor specific T cell immunity. Immunotechnology 1996;2: 241-51.
2. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-82.
3. Ioannidis CG, Fisk B, Fan D, Biddision WA, Wharton JT, O'Brian CA. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER2/neu proto-oncogene. Cell Immunol 1993;151: 225-34.
4. Dyall R, Bowne WB, Weber LW, Lemaoult J, Szabo P, Moroi Y, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-61.
5. Grohmann U, Fioretti MC, Bianchi R, Belladonna ML, Ayroldi E, Surace D, et al. Dendritic cells, interleukin 12 and CD4+ lymphocytes in the initiation of class I restricted reactivity to a tumor/self peptide. Crit Rev Immunol 1998;18:87-98.
6. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201 specific peptides from prostate specific membrane. Prostate 1996;29:371-80.
7. Mortarini RA, Anichini A, DeNicola M, Siena S, Bregni M, Belli F, et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of Melan-a/Mart-127-35-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursor. Cancer Res 1997; 57:5534-41.
8. Van Elsas A, Van der Burg SH, Van der Minne CE, Borghi M, Mourer JS, Melief CJ, et al. Peptide pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A0201 binding peptides from the melan-A/MART-1 self antigen. Eur J Immunol 1996;26:1683-9.
9. Carbone FR, Moore MW, Sheil JM, Bevan MJ. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J Exp Med 1988;167:1767-79.
10. Kelly JM, Sterry SJ, Cose S, Turner SJ, Fecondo J, Rodda S, et al. Identification of conserved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major higtocompatibility complex class I bound determinat. Eur J Immunol 1993;23:3318-26.
11. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998; 4:585-93.
12. Caux P, Favre N, Bonnotte B, Moutet M, Martin M, Martin F. Tumor infiltrating dendritic cells are defective in their antigen presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. Adv Exp Med Biol 1997;417:525-8.
13. Pickl WF, Majdic O, Kohl P, Stockl J, Tiedl E, Scheinecker C, et al. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol 1996;157:3850-9.
14. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991;51:4257-65.
15. Dooms H, Desmedt M, Vancaeneghem S, Rottier P, Goossen V. Quiescence-Inducing and Antiapoptotic activities of IL-15 Enhance secondary CD4+ T Cell Responsiveness to Antigen. J Immunol 1998;161:2141-50.
16. Anderson DM, Johnson L, Glaccum MB, Copeland NG, Gilbert DJ, Jenkins NA, et al. Chromosomal assignment and genomics structure of IL-15. Genomics 1995;25:701-6.
17. Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT, Ioannides CG. Ovarian cancer associated lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol 1998;5:743-50.
18. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of the HER2/neu proto-oncogene recognized by ovarian tumor specific CTL lines. J Exp Med 1995;181:2709-17.
19. Anderson BW, Swearingen BJ, Wharton JT, Ioannides CG. Primary generation of human antitumor CTL by a HLA-A2 restricted HER-2 peptide. Proc of AACR 1997; 38:A1606.
20. People GE, Coedegebuure PS, Smith R, Lindhan DC, Yoshino I, Eberlein TJ. Breast and ovarian caner specific cytotoxic T lymphocytes recognize the same HER2/neu derived peptide. Proc Natl Acad Sci USA 1995;92:432-6.
21. Kim DK, Lee TV, Castilleja A, Anderson BW, People GW, Kudelka JM, et al. Folate binding protein peptide 191-199 presented on dendritic cell can stimulate CTL form ovarian and breast cancer patients. Anticancer Res 1999;19:2907-16.
22. Doherty TM, Sedar RA, Sher A. Induction and regulation of IL-15 expression in murine macrophage. J Immunol 1996;156:735-41.
23. Giri JG, Anderson DM, Kumaki S, Park LS, Grabstein KH, Cosman D. A novel T cell growth factor that share activities and receptor components with IL-2. J Leukoc Biol 1995;57:763-6.
24. Kumaki S, Armitage R, Ahdieh M, Park L, Cosman D. Interleukin-15 up-regulates interleukin-2 receptor α-chain but down-regulates its own high-affinity binding sites on human T and B cells. Eur J Immunol 1996;26: 1235-9.
25. Repmann R, Wagner S, Richter A. Adjuvant therapy of renal cell carcinoma with active specific immunotherapy using autologous tumor vaccine. Anticancer Res 1997;17:2879-82.
26. Fujita K, Ikarashi H, Tanaka K, Kodama S, Tokunaga A, Takahashi T, et al. Prolonged disease free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor infiltrating lymphocytes. Clin Cancer Res 1995;1:501-7.
27. Blankenstein T, Cayeux S, Qin Z. Genetic approaches to cancer immunotherapy. Rev Physiol Biochem Pharmacol 1996;129:1-49.
28. Blankenstein T, Qin Z, Uberla K. Tumor suppression after tumor cell targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991;173:1047-52.
29. Bubenik J, Simova J, Jandlova T. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 1990;23:287-92.
30. Aoki T, Tashiro K, Miyatake SIY, Kasid A. Expression of murine IL-7 in a murine glioma cell line results in reduce tumorigenicity in vivo. Proc Natl Acad Sci USA 1992;89:3850-4.
31. Li W, Diamantstein T, Blankensten T. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol Immunol 1990;27:1331-7.
32. Henderson RA, Nimgaonkar MT, Watkins SC, Robbind PD, Ball ED, Finn OJ. Human dendritic cells genetically engineered to express high level of the human epithelian tumor antigen Mucin (MUC-1). Cancer Res 1996;56: 3763-70.
33. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with Mannan-MUC-1 fusion protein. J Clin Invest 1997; 100:2783-92.
34. Zaks TZ, Rosenberg SA. Immunization with peptide epitope (p369-377) from HER-2/neu lead to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumor. Cancer Res 1998;58:4902-8.
35. Fisk B, Chesak B, Pollack M, Wharton JT, Ioannides CG. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol 1994;157:412-27.
36. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T cells specific for peptides derived from the HER-2/neu proto-oncogene protein. Cancer Res 1994;54:1071-6.